Table 2 In vivo and ex vivo 1H and 31P-MRS metabolic analysis of HT29 subcutaneous tumours and extracts following MK-2206 treatment

From: Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma

In vivo 1H-MRS of subcutaneous HT29 xenografts

 

Vehicle-control (n = 5)

MK-2206 (n = 5)

Pre

Post

Pre

Post

Corrected tCho/water ratio x 10−3

8.05 ± 1.11

6.25 ± 1.84

9.22 ± 1.42

4.33 ± 1.03

 

P = 0.31

**P = 0.04

Ex vivo 1H and 31P-MRS of subcutaneous HT29 tumour extracts

 

Vehicle-control

MK-2206

P

PE

1.27 ± 0.10

1.28 ± 0.11

0.96

PC

1.95 ± 0.12

1.60 ± 0.09

0.04*

GPE

1.21 ± 0.14

0.87 ± 0.07

0.03*

GPC

2.51 ± 0.13

1.94 ± 0.18

0.04*

Lactate

5.81 ± 0.58

7.78 ± 0.92

0.10

Alanine

1.49 ± 0.15

1.27 ± 0.08

0.25

Glucose

0.79 ± 0.10

0.70 ± 0.13

0.61

Glutamine

1.01 ± 0.06

0.72 ± 0.02

0.002*

Glutamate

2.67 ± 0.23

1.56 ± 0.30

0.02*

Aspartate

0.35 ± 0.04

0.20 ± 0.05

0.05*

Glycine

0.67 ± 0.11

0.37 ± 0.06

0.04*

Glutathione

1.30 ± 0.11

0.85 ± 0.08

0.007*

Creatine

3.82 ± 0.21

2.87 ± 0.19

0.008*

Phosphocreatine

1.20 ± 0.08

0.74 ± 0.08

0.004*

ATP + ADP

1.38 ± 0.08

1.07 ± 0.07

0.02*

  1. Data are expressed as µmol/g wet weight and presented as the mean  ±  sem, n  ≥  5 in each group. Two-tailed unpaired t test was used to compare MK2206-treated tumour extracts with vehicle-treated controls and *P  ≤  0.05 is considered significant.
  2. **Statistically significant when compared the pre-MK-2206 treatment values with post-treatment. Two-tailed paired t test was used and data are expressed as mean ± sem
Back to article page